Irinotecan and Cisplatin for High Grade Neuroendocrine Carcinoma of the Gastrointestinal Tract
Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
1. Assess the clinical activity defined by response rate of irinotecan and cisplatin in
untreated patients with metastatic or unresectable high grade neuroendocrine carcinoma of the
gastrointestinal tract.
Secondary Objective:
1. To assess the safety profile of irinotecan and cisplatin in untreated patients with
metastatic or unresectable high grade neuroendocrine carcinoma of the gastrointestinal tract.